News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phage Biotechnology Corp. Engages The Bruckner Group To Find A Joint Commercialization Partner For Phage's Portfolio Of Recombinant Protein Biopharmaceuticals, Technologies, and Development Platforms


11/6/2007 9:36:53 AM

WAKEFIELD, Mass.--(BUSINESS WIRE)--The Bruckner Group is pleased to announce that Phage Biotechnology Corp. (“Phage”) has engaged The Bruckner Group to find a partner to jointly commercialize Phage’s portfolio of recombinant biological therapies, the products of Phage’s development platforms and technologies. The Phage portfolio includes ten innovative and standard-of-care recombinant proteins, including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies (which will compete with monoclonal antibodies). Phage anticipates its portfolio will produce a revenue stream in the moderate nine-figure range within four years, and a medium to high ten-figure range eventually. Phage’s development platforms include a single-chain antibody development platform, a new proprietary pegylation technology, and a new recombinant protein manufacturing process that avoids existing protein process manufacturing patents.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES